Physician
Texas Oncology PA
Texas Oncology PA was paid $4.12M by Medicaid between Jan 2018 and Dec 2024, across 82 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 45% of everything it billed.
33Billing provider infoTEXAS ONCOLOGY PA
EL PASO, TX 79915
EL PASO, TX 79915
33aNPI1811944101assigned 05/30/2006
33bProvider typeHematology & Oncology Physician
28Total paid$4.12M
24GClaims532,337
24DCodes billed82
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in Texas
Rank by total paid#1 of 49
Median peer was paid$15K
This provider vs. median269×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 86,842 | $176K | |
| 2019 | 70,805 | $141K | |
| 2020 | 65,197 | $266K | |
| 2021 | 127,809 | $1.15M | |
| 2022 | 88,970 | $1.08M | |
| 2023 | 73,568 | $962K | |
| 2024incomplete | 19,146 | $341K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 45% | 74,525 | 65,054 | $1.85M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 10.0% | 8,526 | 5,229 | $410K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 9.8% | 140,082 | 109,761 | $404K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.8% | 21,089 | 19,908 | $403K |
| 80053 | Comprehensive metabolic panel | 8.7% | 93,561 | 76,890 | $359K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 3.5% | 4,981 | 1,146 | $143K |
| 77427 | 1.7% | 740 | 318 | $72K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.3% | 1,067 | 824 | $52K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 1.2% | 1,077 | 644 | $50K |
| 83615 | <1% | 18,933 | 16,268 | $31K | |
| G6002 | Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy | <1% | 540 | 88 | $30K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,693 | 1,158 | $30K |
70 more codes
| 96367 | <1% | 2,582 | $29K | |
| 82728 | <1% | 10,326 | $24K | |
| 77336 | <1% | 514 | $21K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 179 | $21K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,733 | $19K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 380 | $19K |
| 83550 | <1% | 10,514 | $17K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 239 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,517 | $15K |
| 83735 | <1% | 2,977 | $14K | |
| 83540 | <1% | 10,495 | $12K | |
| 77334 | <1% | 120 | $12K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 126 | $6K |
| 85055 | <1% | 711 | $6K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 49 | $4K |
| 77290 | <1% | 13 | $4K | |
| 77300 | <1% | 30 | $4K | |
| 51798 | <1% | 495 | $3K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 27 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,137 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 32 | $2K |
| 81003 | <1% | 1,522 | $2K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 63 | $2K |
| 85027 | <1% | 403 | $2K | |
| 86304 | <1% | 163 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 40 | $1K |
| 85046 | <1% | 506 | $1K | |
| 96417 | <1% | 154 | $1K | |
| 99205 | Prolong outpt/office vis | <1% | 24 | $1K |
| 85007 | <1% | 403 | $986.40 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,147 | $921.46 |
| 84100 | <1% | 227 | $891.41 | |
| 77263 | <1% | 13 | $820.02 | |
| 84460 | <1% | 300 | $706.23 | |
| 84450 | <1% | 300 | $693.02 | |
| 84075 | <1% | 300 | $690.55 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 41 | $680.57 |
| 82247 | <1% | 300 | $669.30 | |
| 82607 | <1% | 105 | $584.36 | |
| 96523 | <1% | 86 | $562.15 | |
| 86300 | <1% | 162 | $476.31 | |
| 82040 | <1% | 170 | $396.12 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 259 | $392.57 |
| 96402 | <1% | 12 | $349.36 | |
| 84155 | <1% | 203 | $318.32 | |
| 82378 | <1% | 68 | $308.46 | |
| 81001 | <1% | 157 | $241.78 | |
| 99223 | Prolong inpt eval add15 m | <1% | 17 | $231.36 |
| 82565 | <1% | 88 | $199.52 | |
| 82310 | <1% | 74 | $182.91 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16 | $179.34 |
| 82374 | <1% | 74 | $172.66 | |
| 84132 | <1% | 74 | $169.17 | |
| 82435 | <1% | 74 | $162.94 | |
| 84520 | <1% | 88 | $153.99 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 97,428 | $124.66 |
| 82746 | <1% | 15 | $64.34 | |
| 84550 | <1% | 189 | $36.70 | |
| 85045 | <1% | 164 | $34.97 | |
| 90686 | <1% | 38 | $17.93 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 116 | $15.80 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 14 | $14.99 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 131 | $0.00 |
| 90653 | 0% | 12 | $0.00 | |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation agreement | 0% | 10,364 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 90 | $0.00 |
| G1007 | Clinical decision support mechanism aim specialty health, as defined by the medicare appropriate use criteria program | 0% | 70 | $0.00 |
| 99024 | 0% | 15 | $0.00 | |
| 90694 | 0% | 19 | $0.00 | |
| 96415 | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHOOK, JASON (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Texas Oncology PA | Dallas, TX | $18K |
| Texas Oncology PA | Beaumont, TX | $10K |
| Texas Oncology PA | Austin, TX | $4K |
| Texas Oncology PA | Webster, TX | $35.80 |
| Texas Oncology PA | Fort Worth, TX | $12.17 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.